BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A

In a study involving patients with severe hemophilia A, an injection of the novel fusion protein BIVV001 resulted in a duration of factor VIII activity that was up to four times as long as that for recombinant factor VIII, an increase that may signal the possibility of weekly therapy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-09, Vol.383 (11), p.1018-1027
Hauptverfasser:	Konkle, Barbara A, Shapiro, Amy D, Quon, Doris V, Staber, Janice M, Kulkarni, Roshni, Ragni, Margaret V, Chhabra, Ekta S, Poloskey, Stacey, Rice, Kara, Katragadda, Suresh, Fruebis, Joachim, Benson, Craig C
Format:	Artikel
Sprache:	eng
Schlagworte:	Anaphylaxis Body weight Coagulation factors Drug dosages Factor VIII deficiency Fusion protein Hemophilia Hypersensitivity Hypothesis testing Injection Intravenous administration Patients Pharmacokinetics Plasma Polypeptides Proteins Quality of life Von Willebrand factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a study involving patients with severe hemophilia A, an injection of the novel fusion protein BIVV001 resulted in a duration of factor VIII activity that was up to four times as long as that for recombinant factor VIII, an increase that may signal the possibility of weekly therapy.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2002699